Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Belief Biomed OK'd to Start China Trials of Gene Therapy for Hemophilia

publication date: Aug 11, 2021

Shanghai Belief Biomed was approved to start China trials of its IV infusion gene therapy for Hemophilia B. It is the first approval of an IV gene therapy for the indication and for a rare disease in China. BBM-H901 is a bio-engineered adeno-associated viral vector using a novel recombinant AAV capsid. The capsid contains a codon-optimized human factor IX gene under the control of a liver-specific promoter. It has shown high efficacy and safety, offering a one-time treatment for Hemophilia B that would liberate patients from regular treatment. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China